Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline

Key Points

• Bictegravir plus lenacapavir maintained virologic suppression in HIV-1 patients at 48 weeks, showing effective treatment.
• The trial involved 128 vis-ssupressed people, demonstrating that both doses of lenacapavir were well tolerated.
• Conducted as a phase 2/3 trial, the findings suggest this combination is a viable alternative to complex regimens.
• The results indicate that bictegravir plus lenacapavir may offer a new pathway for maintaining HIV-1 control among patients.